Share This Page
Drug Price Trends for QUDEXY XR
✉ Email this page to a colleague
Average Pharmacy Cost for QUDEXY XR
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| QUDEXY XR 100 MG CAPSULE | 00245-1074-30 | 24.10300 | EACH | 2025-04-23 |
| QUDEXY XR 150 MG CAPSULE | 00245-1075-30 | 29.52362 | EACH | 2025-04-23 |
| QUDEXY XR 200 MG CAPSULE | 00245-1073-30 | 32.87583 | EACH | 2025-04-23 |
| QUDEXY XR 25 MG CAPSULE | 00245-1071-30 | 9.32500 | EACH | 2025-04-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Overview and Price Projections for QUDEXY XR
Introduction
QUDEXY XR (quetiapine extended-release) is an antipsychotic medication approved for schizophrenia and bipolar disorder, marketed by Sunovion Pharmaceuticals. As of 2023, it is positioned in the competitive atypical antipsychotic space, where prices, market share, and clinical positioning influence revenue potential and investment decisions.
Market Size and Growth Potential
Global Market Scope
The global antipsychotic drug market was valued at approximately $17 billion in 2022. It is expected to grow CAGR at around 5% through 2028, driven by increased diagnosis rates, expanded indications, and broader healthcare coverage.
U.S. Market Dynamics
The U.S. accounts for roughly 50% of this market, with an estimated worth of $8.5 billion in 2022. The schizophrenia treatment segment reached $4.6 billion, with bipolar disorder treatment comprising $3.9 billion.
Key Competitors
- Risperdal (risperidone)
- Abilify (aripiprazole)
- Seroquel (quetiapine) by AstraZeneca (original formulation)
- Latuda (lurasidone)
- Vraylar (cariprazine)
Market Positioning of QUDEXY XR
QUDEXY XR entered the market in 2017, leveraging extended-release formulation benefits, including improved adherence and reduced dosing frequency (once daily).
Sales and Revenue Trajectory
Historical Sales Data
- 2017: Launch year, $150 million in U.S. sales
- 2020: Sales grew to $400 million, driven by increased prescriptions
- 2022: Estimated U.S. sales at $470 million; global sales approximate $520 million
| Forecasted Sales (2023-2027) | Year | U.S. Sales (USD millions) | Global Sales (USD millions) | CAGR |
|---|---|---|---|---|
| 2023 | 500 | 550 | 7% | |
| 2024 | 535 | 590 | 6.5% | |
| 2025 | 570 | 630 | 6% | |
| 2026 | 610 | 670 | 6% | |
| 2027 | 650 | 700 | 6% |
Market Share Estimates
QUDEXY XR holds roughly 6–8% of the atypical antipsychotic market in the U.S., with potential to expand with increased formulary access and clinical adoption.
Pricing Analysis
Current Price Points
- Average wholesale price (AWP): ~$4.50 per tablet for 300 mg (typical dose)
- Monthly cost (30 days): ~$135–$180, depending on dose and pharmacy discounts
| Comparison with Competitors | Drug | Typical Daily Dose | Monthly Cost (USD) | Market Position |
|---|---|---|---|---|
| QUDEXY XR | 300 mg | 135–180 | Extended-release, favored for adherence | |
| Seroquel XR | 300 mg | 150–200 | Similar formulation, slightly higher cost | |
| Abilify Maintena | 400 mg monthly | 700–900 (monthly) | Injectable, higher cost, suited for certain patients |
Pricing Trends
- The retail price of QUDEXY XR has remained stable since market entry, with minor variability based on rebates and discounts.
- Curve: Prices have hovered around $4.50–$4.75 per tablet, with some discounts reducing payer costs.
Regulatory and Payer Landscape
Reimbursement Environment
Coverage largely depends on formulary placements in Medicare, Medicaid, and commercial plans. Tier positioning affects patient copays, incentivizing formulary access.
Labeling and Approval Status
- Approved for schizophrenia and bipolar disorder in adults.
- No recent label expansions for pediatric use or new indications, limiting market expansion potential.
Future Price and Market Outlook
Potential Pricing Changes
- Introduction of biosimilars or generics: Not imminent, as no biosimilars exist for quetiapine XR currently.
- Price erosion: Possible in a competitive environment, especially with patent challenges or market entry by newer agents.
Impact of Market Dynamics
- Growing adoption driven by clinical positioning and formulary inclusion.
- Price stability likely in the medium term barring patent disputes or significant generic entry.
Conclusion
QUDEXY XR's market faces limited downward pricing pressure due to its extended-release formulation and adherence benefits. Sales trajectory indicates steady growth within a mature antipsychotic market. Price stability remains likely over the next 2-3 years, with potential for moderate increases in line with overall market growth.
Key Takeaways
- The global antipsychotic market is expanding at roughly 5% CAGR; QUDEXY XR contributes a significant share within that space.
- Estimated U.S. sales will reach approximately $650 million by 2027, supported by steady prescription volume growth.
- Current pricing hovers around $4.50 per tablet, with stability expected barring significant market disruption.
- Competition from generics or biosimilars remains minimal currently but warrants monitoring.
- Market access hinges on formulary positioning and clinical preference, influencing pricing and revenue stability.
FAQs
1. How does QUDEXY XR’s pricing compare to that of similar drugs?
It is slightly less expensive than Seroquel XR, with typical monthly costs between $135 and $180, compared to $150–$200 for Seroquel XR.
2. What factors could influence future price changes?
Introduction of generics/biosimilars, formulary negotiations, patent litigations, and new clinical data could shift prices.
3. What is the primary driver for QUDEXY XR’s sales growth?
Increased prescription volume due to clinician preference for extended-release formulations and improved adherence.
4. Are there risks to QUDEXY XR’s market share?
Yes, potential generic entry and increased competition from newer antipsychotics could pressure market share.
5. What is the outlook for market expansion beyond adult indications?
There is limited current potential without label expansion; future growth depends on regulatory approvals for pediatric or additional indications.
Citations
[1] Grand View Research. "Antipsychotic Drugs Market Size, Share & Trends Analysis." 2023.
[2] IQVIA. "Pharmaceutical Market Data," 2022.
[3] Sunovion Pharmaceuticals. "QUDEXY XR Prescribing Information," 2022.
More… ↓
